We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $47.9M invested in NKGen Biotech, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

27% less capital invested

Capital invested by funds: $65.3M → $47.9M (-$17.4M)

48% less funds holding

Funds holding: 25 → 13 (-12)

92% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 13

Holders
13
Holders Change
-12
Holders Change %
-48%
% of All Funds
0.21%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
1
Increased
3
Reduced
3
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
+$21M
2
DC
Diametric Capital
Massachusetts
+$4.79M
3
RCM
Rivernorth Capital Management
Florida
+$756K
4
CS
Clear Street
New York
+$745K

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$6.63M
2
MF
Magnetar Financial
Illinois
-$6.41M
3
FTCM
Fir Tree Capital Management
New York
-$5.68M
4
UOC
UBS O'Connor
Illinois
-$3.27M
5
KL
KIM LLC
Kansas
-$3.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
MC
1
Meteora Capital
Florida
$17.6M +$21M +2,067,811 +3,766%
RCM
2
Rivernorth Capital Management
Florida
$6.01M +$756K +74,325 +15%
SIM
3
Sandia Investment Management
Massachusetts
$4.91M -$295K -29,000 -6%
DC
4
Diametric Capital
Massachusetts
$3.91M +$4.79M +471,000 New
PC
5
Periscope Capital
Ontario, Canada
$3.61M – – –
KIM
6
Karpus Investment Management
New York
$2.91M -$120K -11,775 -4%
Balyasny Asset Management
7
Balyasny Asset Management
Illinois
$2.58M – – –
AIMCA
8
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.66M – – –
MTCM
9
Mint Tower Capital Management
Netherlands
$1.66M – – –
WCMNY
10
Westchester Capital Management (New York)
New York
$1.09M – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$835K – – –
CS
12
Clear Street
New York
$609K +$745K +73,242 +60,034%
SFM
13
Spartan Fund Management
Canada
$523K -$1.82M -178,466 -74%
RCM
14
Radcliffe Capital Management
Pennsylvania
– -$6.63M -641,462 Closed
MF
15
Magnetar Financial
Illinois
– -$6.41M -620,574 Closed
FTCM
16
Fir Tree Capital Management
New York
– -$5.68M -549,428 Closed
UOC
17
UBS O'Connor
Illinois
– -$3.27M -316,204 Closed
KL
18
KIM LLC
Kansas
– -$3.1M -300,000 Closed
GF
19
Gabelli Funds
New York
– -$2.43M -235,396 Closed
FBCM
20
Fort Baker Capital Management
California
– -$2.08M -201,147 Closed
ACM
21
Atalaya Capital Management
New York
– -$1.55M -150,000 Closed
GCIA
22
Gabelli & Co Investment Advisers
New York
– -$890K -86,200 Closed
Walleye Capital
23
Walleye Capital
New York
– -$867K -83,919 Closed
Walleye Trading
24
Walleye Trading
New York
– -$488K -47,286 Closed
VF
25
Virtu Financial
New York
– -$127K -12,332 Closed
1
2

NKGN Hedge Fund Activity: Q3 2023 in Review

13 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2023, worth a combined $47.9M — down 27% from $65.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NKGN and 1 opened new positions — a net loss of 12 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Meteora Capital, adding an estimated $21M. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $6.63M sold.

  • 13 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2023, down from 25 in Q2 2023.
  • Funds reported $47.9M of NKGen Biotech, Inc. Common Stock stock for Q3 2023, down 27% quarter-over-quarter.
  • 1 fund opened new NKGen Biotech, Inc. Common Stock positions in Q3 2023 and 13 closed out, a net change of -12 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2023 was Meteora Capital, an estimated $21M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q3 2023 was Radcliffe Capital Management, an estimated $6.63M sold.

Based on aggregated 13F filings for Q3 2023.